OncoZenge AB Logo

OncoZenge AB

Developing a non-opioid lozenge for oral pain relief in cancer patients.

ONCOZ | ST

Overview

Corporate Details

ISIN(s):
SE0015504097
LEI:
2549003980RBCR6NIF38
Country:
Sweden
Address:
Gustavslundsvagen 34, 5 tr, 167 51 Bromma
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

OncoZenge AB is a pharmaceutical company focused on developing innovative treatments for oral pain. Its lead candidate, BupiZenge™, is a novel lozenge formulation that utilizes the well-established local anesthetic bupivacaine to provide targeted, non-opioid pain relief. The primary indication is oral mucositis, a debilitating side effect of cancer radiotherapy and chemotherapy that represents a significant unmet medical need. By alleviating pain locally, BupiZenge™ aims to improve patients' quality of life, reduce the need for systemic opioids, and prevent hospitalizations. Having successfully completed Phase 1 and 2 trials and received regulatory guidance from the EMA and FDA, the company is preparing for Phase 3 studies and establishing commercial partnerships for market entry. The treatment also has potential applications for other oral pain conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all OncoZenge AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for OncoZenge AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for OncoZenge AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-07 Stian Kildal Other Buy 20,439 85,026.24 SEK

Peer Companies

Read Gene Spolka Akcyjna Logo
Develops DNA tests to identify genetic cancer risk for early detection and prevention.
Poland
RDG
RELIEF Therapeutics Holding AG Logo
Developing and commercializing novel therapies for rare and ultra-rare diseases.
Switzerland
RLF
RYVU Therapeutics S.A. Logo
Clinical-stage drug discovery company developing novel small molecule therapies for oncology.
Poland
RVU
SAREUM HOLDINGS PLC Logo
Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.
United Kingdom
SAR
SCANCELL HOLDINGS PLC Logo
Developing therapeutic vaccines and antibodies for cancer and infectious diseases.
United Kingdom
SCLP
SCIENCE GROUP PLC Logo
International science & tech consultancy providing advisory, R&D, and product development.
United Kingdom
SAG
Selvita S.A. Logo
Preclinical CRO offering integrated drug discovery and development services for life sciences.
Poland
SLV
Simris Group AB Logo
Develops novel cyanobacteria-based payloads for Antibody-Drug Conjugates to treat cancer.
Sweden
SIMRIS
SKINBIOTHERAPEUTICS PLC Logo
A life science company developing microbiome-based skin health products and supplements.
United Kingdom
SBTX
Terranet B Logo
Develops ultra-fast ADAS anti-collision technology for automakers to protect vulnerable road users.
Sweden
TERRNT

Talk to a Data Expert

Have a question? We'll get back to you promptly.